Parker Hannifin has announced a major investment in its Parker Bioscience division, which supplies and delivers systems for upstream and downstream pharmaceutical and biopharmaceutical manufacturing. The division has sites in Birtley, UK and Oxnard, CA in the US.
The investment will expand Parker Bioscience’s laboratory, clean room, office and warehouse facilities. According to the company, it also will make the division’s Birtley premises “one of the most modern manufacturing sites for integrated bioprocessing solutions in EMEA.”
Mike Brailsford, General Manager at Parker Bioscience, said: “The increased capacity will help us to offer larger scale services to biopharmaceutical manufacturers in Europe and across the globe, and is a major milestone in the division’s growth.”
Parker Bioscience has not responded to a request for comment.